Results 21 to 30 of about 3,144,476 (264)

The Role and Mechanism of Innate Immune Regulation in Overcoming Oxaliplatin Resistance and Enhancing Anti-Tumor Efficacy in Colorectal Cancer [PDF]

Pharmaceuticals
Background/Objectives: The reversal effect of cGAMP, as a STING pathway regulator, on oxaliplatin resistance in colorectal cancer was investigated, and its mechanism was proposed.
Xiaoqing Wang, Meili Xi, Xing Lu, Xiangshi Tan   +3 more
doaj   +2 more sources

TGM2, HMGA2, FXYD3, and LGALS4 genes as biomarkers in acquired oxaliplatin resistance of human colorectal cancer: A systems biology approach.

PLoS ONE, 2023
Acquired resistance to oxaliplatin is considered as the primary reason for failure in colorectal cancer (CRC) therapy. Identifying the underlying resistance mechanisms may improve CRC treatment.
Tayebeh Cheraghi-Shavi, Razieh Jalal, Zarrin Minuchehr   +2 more
doaj   +2 more sources

A Novel Protein Encoded by Exosomal CircATG4B Induces Oxaliplatin Resistance in Colorectal Cancer by Promoting Autophagy

Advanced Science, 2022
Oxaliplatin is commonly used in chemotherapeutic regimens for colorectal cancer (CRC) after surgical resection. However, acquired chemoresistance seriously affects the curative effect in CRC patients, and the mechanism is still unclear.
Zihao Pan, Jun Zheng, Jiebin Zhang, Jiatong Lin, Jianguo Lai, Zejian Lyu, Huolun Feng, Junjiang Wang, Deqing Wu, Yong Li   +9 more
doaj   +2 more sources

Mechanical forces inducing oxaliplatin resistance in pancreatic cancer can be targeted by autophagy inhibition. [PDF]

Commun Biol
Pancreatic cancer remains one of the most lethal malignancies, with limited treatment options and poor prognosis. A common characteristic among pancreatic cancer patients is the biomechanically altered tumor microenvironment (TME), which among others is ...
Kalli M, Mpekris F, Charalambous A, Michael C, Stylianou C, Voutouri C, Hadjigeorgiou AG, Papoui A, Martin JD, Stylianopoulos T.   +9 more
europepmc   +2 more sources

Upregulation of CRABP2 by TET1-mediated DNA hydroxymethylation attenuates mitochondrial apoptosis and promotes oxaliplatin resistance in gastric cancer

Cell Death and Disease, 2022
Oxaliplatin is the main chemotherapy drug for gastric cancer (GC), but quite a few patients are resistant to oxaliplatin, which contributes to the poor prognosis of GC patients.
Xiaolong Tang, Yahang Liang, Guorui Sun, Qingsi He, Zhenyu Hou, Xingzhi Jiang, Peng Gao, Hui Qu   +7 more
doaj   +2 more sources

HOTAIR/miR-1277-5p/ZEB1 axis mediates hypoxia-induced oxaliplatin resistance via regulating epithelial-mesenchymal transition in colorectal cancer

Cell Death Discovery, 2022
The hypoxic microenvironment contributes to the chemoresistance of many malignant tumors including colorectal cancer (CRC). Accumulating studies have indicated that long non-coding RNAs (lncRNAs) play important roles in chemotherapy resistance.
Xingyue Weng, Hao Liu, Jian Ruan, Miaoyan Du, Lingjie Wang, Jiayan Mao, Ying Cai, Xuemei Lu, Wei Chen, Yaqing Huang, Xiao Zhi, Jianzhen Shan   +11 more
doaj   +2 more sources

TRIM29 Reverses Oxaliplatin Resistance of P53 Mutant Colon Cancer Cell [PDF]

Canadian Journal of Gastroenterology and Hepatology, 2021
Background. Oxaliplatin is the first-choice chemotherapy method for patients with advanced colon cancer. However, its resistance leads to treatment failure for many patients.
Guoqiong Lei, Sushun Liu, Xin Yang, Chao He   +3 more
doaj   +3 more sources

The expression of exosomal and cellular miRNAs in predicting oxaliplatin resistance in colorectal cancer cells: an in silico and in vitro study. [PDF]

BMC Cancer
Colorectal cancer (CRC) is a common gastrointestinal cancer, and even though oxaliplatin chemotherapy is effective, there is a high likelihood of relapse, indicating the presence of oxaliplatin-resistant CRC.
Deli H, Vakili-Ghartavol Z, Asgari Y, Tavoosidana G, Eftekhar E, Ghahremani MH.   +5 more
europepmc   +2 more sources

METTL3 confers oxaliplatin resistance through the activation of G6PD-enhanced pentose phosphate pathway in hepatocellular carcinoma. [PDF]

Cell Death Differ
Oxaliplatin-based therapeutics is a widely used treatment approach for hepatocellular carcinoma (HCC) patients; however, drug resistance poses a significant clinical challenge.
Jin X, Lv Y, Bie F, Duan J, Ma C, Dai M, Chen J, Lu L, Xu S, Zhou J, Li S, Bi J, Wang F, Xie D, Cai M.   +14 more
europepmc   +2 more sources

Upregulated lncRNA PRNT promotes progression and oxaliplatin resistance of colorectal cancer cells by regulating HIPK2 transcription. [PDF]

World J Gastrointest Oncol
BACKGROUND Colorectal cancer (CRC) is the third most common cancer and a significant cause of cancer-related mortality globally. Resistance to chemotherapy, especially during CRC treatment, leads to reduced effectiveness of drugs and poor patient ...
Li SN, Yang S, Wang HQ, Hui TL, Cheng M, Zhang X, Li BK, Wang GY.   +7 more
europepmc   +2 more sources